PI3K/AKT-IN-1 是一种有效的 PI3K/AKT 双重抑制剂 (PI3Kγ、PI3Kδ 和 AKT 的 IC₅₀分别为 6.99 μM、4.01 μM 和 3.36 μM)。PI3K/AKT-IN-1 具有抗癌活性，其作用机制是抑制 PI3K/AKT 通路，诱导 caspase 3 依赖性凋亡 (apoptosis)。

PI3K/AKT-IN-1 is an effective PI3K/AKT dual inhibitor (IC 50 of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent apoptosis.

Solid

PI3Kγ 6.99 μM (IC50) PI3Kδ 4.01 μM (IC

PI3K/AKT-IN-1 (compound 7f) (0.04-100 μM; 48 hours) has high cytotoxic activity on both cell lines with better activity on leukaemia cell line (K562 IC50=2.62 μM) than on the breast cancer cell line (MCF-7 IC50=3.22 μM).
PI3K/AKT-IN-1 (2.62 μM) can promote S-phase cell cycle arrest and apoptosis induction in K562 cells.
PI3K/AKT-IN-1 (2.62 μM; 48 hours) causes an increase in the percentage of Annexin-V positive apoptotic cells both in the early and late stage.
PI3K/AKT-IN-1 (2.62 μM; 48 hours) markedly reduces the expression of PI3K, AKT, Cyclin D1 and NF-κB. has not independently confirmed the accuracy of these methods. They are for reference only.

PI3K/AKT-IN-1 (2000 mg/kg; p.o.; single) is non-toxic and is well tolerated by experimental animals. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female rats (180-200g)

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. El-Dydamony NM, et al. Pyrimidine-5-carbonitrile based potential anticancer agents as apoptosis inducers through PI3K/AKT axis inhibition in leukaemia K562. J Enzyme Inhib Med Chem. 2022;37(1):895-911.

In Vitro: DMSO : 50 mg/mL (107.41 mM; Need ultrasonic)配制储备液